Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Ellipta“
Suchtreffer
Begriffe & Kennungen
Anoro Ellipta (previously Anoro) · 4.8 Undesirable effects · 1
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · 6 from spontaneous reporting. The clinical development programme included 2 354 patients who received umeclidi
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · Infections and infestations Urinary tract infection Common Sinusitis Common Nasopharyngitis Common Pharyngitis
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · Summary of the safety profile
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · System Organ Class Adverse reactions Frequency
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · The frequencies assigned to the adverse reactions identified in the table below include crude incidence rates
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · The most frequently reported adverse reaction is nasopharyngitis (9%).
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · The safety profile of ANORO ELLIPTA is based on safety experience with umeclidinium/vilanterol and the individ
Eintrag öffnenElebrato Ellipta
Eintrag öffnenElebrato Ellipta · 4.1 Therapeutic indications · 1
Eintrag öffnenElebrato Ellipta · 4.3 Contraindications · 1
Eintrag öffnenElebrato Ellipta · 4.3 · 3 Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Eintrag öffnenElebrato Ellipta · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenElebrato Ellipta · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenElebrato Ellipta · 4.5 · 6 Hypokalaemia
Eintrag öffnenElebrato Ellipta · 4.5 · Beta2-adrenergic blockers may weaken or antagonise the effect of beta2-adrenergic agonists, such as vilanterol
Eintrag öffnen